000307385 001__ 307385
000307385 005__ 20260218120819.0
000307385 0247_ $$2doi$$a10.1016/j.ijrobp.2025.12.018
000307385 0247_ $$2pmid$$apmid:41422918
000307385 0247_ $$2ISSN$$a0360-3016
000307385 0247_ $$2ISSN$$a1879-355X
000307385 037__ $$aDKFZ-2025-03029
000307385 041__ $$aEnglish
000307385 082__ $$a610
000307385 1001_ $$aFuchs, Frederik$$b0
000307385 245__ $$aMulti-Institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy.
000307385 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000307385 3367_ $$2DRIVER$$aarticle
000307385 3367_ $$2DataCite$$aOutput Types/Journal article
000307385 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766416891_3634861
000307385 3367_ $$2BibTeX$$aARTICLE
000307385 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307385 3367_ $$00$$2EndNote$$aJournal Article
000307385 500__ $$aepub / Autoren checken
000307385 520__ $$aStereotactic ablative body radiation therapy (SABR) is commonly delivered in multiple fractions, whereas single-fraction (SF) SABR remains uncommon. Magnetic resonance (MR) guided linacs provide superior soft-tissue contrast compared to cone-beam computed tomography on conventional linacs, online adaptive replanning, continuous intrafraction visualization, and automatically triggered beam delivery, potentially enabling safe and effective SF-SABR.We retrospectively analyzed patients treated with MR-guided SF-SABR on a 0.35 Tesla MR-linac at two centers in XXX and XXX (anonymized for review). Median SF-SABR doses were 28 Gy (range: 28-40 Gy) for liver lesions, 30 Gy (range: 28-34 Gy) for lung lesions, 25 Gy for adrenal gland lesions and lymph nodes, and 26 Gy (range: 25-26 Gy) for renal lesions. Endpoints included local control (LC), progression-free survival (PFS), overall survival (OS), and toxicity graded according to CTCAE v5.0.Between April 2020 and December 2024, 161 patients with 175 lesions underwent MR-guided SF-SABR. Lesion distribution was liver (48.0%), lung (42.9%), adrenal gland (4.3%), lymph nodes (3.4%), and kidney (1.9%). Median gross tumor volume (GTV) and planning target volume were 2.4 cc (range: 0.2-83.3 cc) and 9.3 cc (range: 1.4-112.1 cc), respectively. At a median follow-up of 19.3 months, LC rates at 1 and 2 years were 99.1% and 93.6%, respectively. PFS rates at 1 and 2 years were 59.3% and 51.4%, while OS rates were 81.8% and 73.4%, respectively. Treatment was well tolerated, with only one acute grade 3 toxicity reported and no acute grade 4-5 or late grade 3-5 toxicities. Colorectal primary tumors were associated with poorer LC (HR 0.226; p=0.023). Larger GTV independently correlated with reduced LC (HR 1.15; p=0.048) and OS (HR 1.05; p=0.001).MR-guided SF-SABR is feasible, safe, and effective across various tumor locations, providing favorable LC with minimal toxicity, warranting further prospective evaluation.
000307385 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000307385 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307385 7001_ $$aHerrera, Roberto$$b1
000307385 7001_ $$aKotecha, Rupesh$$b2
000307385 7001_ $$aRubens, Muni$$b3
000307385 7001_ $$aRoy, Mukesh$$b4
000307385 7001_ $$aMittauer, Kathryn E$$b5
000307385 7001_ $$aMansoorian, Sina$$b6
000307385 7001_ $$aKaiser, Adeel$$b7
000307385 7001_ $$aKalman, Noah$$b8
000307385 7001_ $$aGaasch, Aurelie$$b9
000307385 7001_ $$aMarschner, Sebastian N$$b10
000307385 7001_ $$aBassiri, Nema$$b11
000307385 7001_ $$aRogowski, Paul$$b12
000307385 7001_ $$aEze, Chukwuka$$b13
000307385 7001_ $$0P:(DE-HGF)0$$aBelka, Claus$$b14
000307385 7001_ $$aCorradini, Stefanie$$b15
000307385 7001_ $$aChuong, Michael D$$b16
000307385 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2025.12.018$$gp. S0360301625066052$$pnn$$tInternational journal of radiation oncology, biology, physics$$vnn$$x0360-3016$$y2025
000307385 8564_ $$uhttps://inrepo02.dkfz.de/record/307385/files/1-s2.0-S0360301625066052-main.pdf$$yOpenAccess
000307385 8564_ $$uhttps://inrepo02.dkfz.de/record/307385/files/1-s2.0-S0360301625066052-main.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000307385 909CO $$ooai:inrepo02.dkfz.de:307385$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000307385 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000307385 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000307385 9141_ $$y2025
000307385 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2022$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000307385 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2022$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-31
000307385 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-31$$wger
000307385 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000307385 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000307385 980__ $$ajournal
000307385 980__ $$aVDB
000307385 980__ $$aUNRESTRICTED
000307385 980__ $$aI:(DE-He78)MU01-20160331
000307385 9801_ $$aFullTexts